Camzyos mavacamten

Drug Class

Cardiac myosin inhibitor

Mechanism

Mavacamten is a cardiac myosin inhibitor that modulates the number of active myosin heads, reducing dynamic left ventricular outflow tract (LVOT) obstruction and improving cardiac contractility and filling.

Approved Indication

Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM).

What This Means For Patients

Camzyos is a cardiac myosin inhibitor approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It targets the underlying mechanism of the disease to improve exercise capacity and symptoms. Following approval by the FDA, EMA, and China NMPA (brand name 迈凡妥), it is available in the Hainan Boao Lecheng pilot zone.

Regulatory Approvals

• FDA — approved (2022) — label
• EMA — approved (2023) — source
• NMPA — approved (2024) — source

Pivotal Clinical Evidence

• EXPLORER-HCM — Olivotto et al., Lancet 2020 (NCT03470545) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215682s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos
• http://www.nmpa.gov.cn/